Zhang Xinlei, Yuan Zengze, Shi Xiawei, Yang Junchao
The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, Zhejiang, China.
The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Front Med (Lausanne). 2025 Mar 20;12:1543571. doi: 10.3389/fmed.2025.1543571. eCollection 2025.
Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible interstitial lung disease characterized by high mortality rates. An expanding body of evidence highlights the critical role of targeted therapies in the management of IPF. Nevertheless, there is a paucity of bibliometric studies that have comprehensively assessed this domain. This study seeks to examine global literature production and research trends related to targeted therapies for IPF.
A literature search was conducted using the Web of Science Core Collection, encompassing publications from 2004 to 2024, focusing on targeted therapies for IPF. The bibliometric analysis utilized tools such as VOSviewer, CiteSpace, and the "bibliometrix" package in R.
A total of 2,779 papers were included in the analysis, demonstrating a general trend of continuous growth in the number of publications over time. The United States contributed the highest number of publications, totaling 1,052, while France achieved the highest average citation rate at 75.74. The University of Michigan Medical School was the leading institution in terms of publication output, with 88 papers. Principal Investigator Naftali Kaminski was identified as the most prolific researcher in the field. The American Journal of Respiratory Cell and Molecular Biology emerged as the journal with the highest number of publications, featuring 98 articles. In recent years, the research has emerged surrounding targeted therapies for IPF, particularly focusing on agents such as TGF-β, pathogenesis, and autotaxin inhibitor.
In this bibliometric study, we systematically analyze research trends related to targeted therapies for IPF, elucidating recent research frontiers and emerging directions. The selected keywords-idiopathic pulmonary fibrosis, targeted therapy, bibliometric analysis, transforming growth factor β, and autotaxin inhibitor-capture the essential aspects of this research domain. This analysis serves as a reference point for future investigations into targeted therapies.
特发性肺纤维化（IPF）是一种进行性且不可逆的间质性肺病，死亡率很高。越来越多的证据凸显了靶向治疗在IPF管理中的关键作用。然而，全面评估该领域的文献计量学研究却很匮乏。本研究旨在考察与IPF靶向治疗相关的全球文献产出及研究趋势。
使用科学网核心合集进行文献检索，涵盖2004年至2024年的出版物，重点关注IPF的靶向治疗。文献计量分析使用了诸如VOSviewer、CiteSpace以及R语言中的“bibliometrix”软件包等工具。
分析共纳入2779篇论文，显示出出版物数量随时间持续增长的总体趋势。美国的出版物数量最多，总计1052篇，而法国的平均被引率最高，为75.74。密歇根大学医学院是发表论文数量最多的机构，有88篇。首席研究员纳夫塔利·卡明斯基被确定为该领域最多产的研究人员。《美国呼吸细胞与分子生物学杂志》成为发表论文数量最多的期刊，有98篇文章。近年来，围绕IPF的靶向治疗出现了相关研究，尤其聚焦于诸如转化生长因子-β、发病机制和自分泌运动因子抑制剂等药物。
在这项文献计量学研究中，我们系统分析了与IPF靶向治疗相关的研究趋势，阐明了近期的研究前沿和新兴方向。所选关键词——特发性肺纤维化、靶向治疗、文献计量分析、转化生长因子-β和自分泌运动因子抑制剂——抓住了该研究领域的关键方面。这一分析可为未来靶向治疗的研究提供参考。
